Abstract:

Purpose: Ki-67 is a nuclear protein expressed outside the G0 phase in the cell cycle. It is used as a indicator of the cells that are proliferated. In patients diagnosed with breast cancer, the Ki-67 proliferation index has been shown to be associated with bad clinical results. This study aims to evaluate the prognostic importance of the Ki-67 proliferation index in patients diagnosed with estrogen receptor and progesterone receptor positive, HER-2 negative, non-axile lymph nod retention. Instrument and Method: Patients diagnosed with operate breast cancer who were diagnosed and monitored in the medical oncology clinic between 2006 and 2014 were included in the study. Immunohistochemically, the Ki-67 nuclear proliferation index was assessed. Relationship with other clinic pathological prognostic factors was assessed. 162 patients were involved in the study. Median 85 (9-132) monthly monitoring in 2 (1.2%) patients local nurses, 7 (4.3%) patients distant metastases were detected. Eight (4.9%) of the patients died. According to the Ki-67 proliferation index, according to the 20% resulting in the Roc curve analysis, patients were divided into two groups. In groups under and above the Ki-67 proliferation index, 7 year overall survival was calculated at 97.1% and 90.9% respectively (p0.042). The Ki-67 proliferation index has a positive correlation with the tumor histological degree, the pathological tumor size, the negative correlation with the hormone receptors. Proliferation is an important indicator used to predict the prognosis and treatment response in breast cancer. Although there is no standard marginal value for the Ki-67 proliferation index, it is not standard in the evaluation and score methodology, it is used in the determination of prognosis along with other clinic pathological prognostic indicators.

Keywords: